Topical Microbial Therapeutics against Respiratory Viral Infections

Trends Mol Med. 2021 Jun;27(6):538-553. doi: 10.1016/j.molmed.2021.03.009. Epub 2021 Apr 17.

Abstract

Emerging evidence suggests that microbial therapeutics can prevent and treat respiratory viral diseases, especially when applied directly to the airways. This review presents established beneficial effects of locally administered microbial therapeutics against respiratory viral diseases and the inferred related molecular mechanisms. Several mechanisms established in the intestinal probiotics field as well as novel, niche-specific insights are relevant in the airways. Studies at cellular and organism levels highlight biologically plausible but strain-specific and host and virus context-dependent mechanisms, underlying the potential of beneficial bacteria. Large-scale clinical studies can now be rationally designed to provide a bench-to-bedside translation of the multifactorial bacterial mechanisms within the host respiratory tract, to diminish the incidence and severity of viral infections and the concomitant complications.

Keywords: microbial therapeutics; microbiome; probiotics; respiratory; viral infection; virus.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Gastrointestinal Microbiome*
  • Humans
  • Immune System / drug effects*
  • Probiotics / therapeutic use*
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / virology
  • Virus Diseases / drug therapy*
  • Virus Diseases / immunology
  • Virus Diseases / virology